SMX Security Matters plc vs GeneDx Holdings Corp — how do they compare? SMX Security Matters plc trades at $3.79 (market cap $4.13M), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 489.1× SMX Security Matters plc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SMX Security Matters plc for 21 Days and GeneDx Holdings Corp for 19 Days on average.
| SMX | WGS | |
|---|---|---|
Market Cap | $4.13M | $2.02B |
Volume | 124,362 | 734,640 |
Sector | Industrials | Health |
52-Week High | $74.08K | $167.51 |
52-Week Low | $3.79 | $34.51 |
Typical Hold Time | 21 Days | 19 Days |
Enterprise Value | -$27.20M | $2.05B |
Signals from Pluang's Aura AI — not financial advice
SMX trades at $3.80, down 2.56% with a bearish technical outlook despite oversold RSI readings. The company shows severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22%. Recent news highlights SMX's digital material passport technology gaining media attention from Forbes, TIME, and Boston Herald in September-October 2026, focusing on recycled plastic verification and circular economy applications.
The stock faces substantial fundamental challenges with no current revenue generation and significant operating losses. While media coverage suggests technological potential in material verification, the absence of revenue and massive negative profitability metrics present extreme risk. Investment viability depends entirely on SMX's ability to monetize its technology platform amid ongoing cash burn.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →